Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 13th Preview)
-
Regulatory milestone in kidney cancer adjuvant therapy
FDA has approved Merck’s adjuvant combination of Welireg (belzutifan) plus Keytruda (pembrolizumab) for patients with clear cell renal cell carcinoma after surgery, setting a new standard for high-risk disease in the post-operative setting. The regimen pairs a HIF-2α inhibitor with an immune checkpoint antibody. The approval follows Dana-Farber research backing the pairing, reflecting a continued push to convert targeted oncology biology into clinically meaningful, durable outcomes in earlier-stage RCC. For Merck, the decision extends Keytruda’s footprint into additional adjuvant and targeted combinations. Clinically, the move puts pressure on alternative adjuvant strategies that do not incorporate HIF-2α pathway modulation, particularly as patient selection for post-surgical intensification becomes more central to regulatory and reimbursement discussions.
-
New IPO wave—record public funding for biotech pipelines
Parabilis Medicines surged to a blockbuster Nasdaq debut, raising about $670 million as the company drives its tumor-focused pipeline forward. The listing follows another record set by obesity biotech Kailera Therapeutics’ roughly $625 million IPO earlier in the year. The renewed IPO momentum has restarted attention on biotech’s access to public capital after years of drought, with analysts pointing to pent-up venture and Big Pharma funding deployed post-pandemic. Industry commentary suggests the IPO reopening is tied to both deal activity in M&A and a backlog of venture-backed programs seeking liquidity. For investors, the message is clear: even amid uncertain macro conditions and a still-evolving regulatory leadership landscape, the market is rewarding clinical narratives and scalable platforms with rapid capital inflows.
-
Funding surge for ultrasound-mediated gene delivery
SonoThera raised an oversubscribed $125 million in a Series B to advance ultrasound-mediated genetic medicines into clinical development. The financing was led by Vida Ventures and includes strategic and financial backers such as ARK Invest, Otsuka Pharmaceutical, UCB Ventures, and Leaps by Bayer. The company plans to progress lead programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease, leveraging its RIPPLE ultrasound delivery approach and PORE payload engineering platform. SonoThera is positioning the platform to support redosing by addressing conventional gene therapy limitations tied to delivery and immune responses. SonoThera said it expects to initiate its first DMD clinical trial in 2027, underscoring that the money is being allocated to clinical readiness and expanding delivery capabilities across tissues.
-
First-in-human partial cell reprogramming enters glaucoma trial
Life Biosciences has dosed the first participant in a gene therapy trial testing partial cellular reprogramming for glaucoma. The approach turns on three genes intended to “partially reprogram” aged cells to restore regenerative properties without fully resetting cell identity. The program is designed to encourage regeneration of optic nerve neurons in adults, a key bottleneck because mature optic nerve neurons do not normally regenerate. Investigators will prioritize safety in this early human setting, where concerns include the risk of abnormal cell states, including tumorigenic potential. By choosing the eye as the first clinical target, Life Biosciences is also betting that localized tissue changes may reduce systemic risk relative to reprogramming in other organs.
-
Late-stage performance in psoriasis—Takeda’s zasocitinib vs Sotyktu
Takeda reported that its oral TYK2 inhibitor zasocitinib (TAK-279) showed statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) in a Phase 3 top-line readout for moderate to severe plaque psoriasis. The data from Takeda’s Latitude Atlas study position zasocitinib as a potential next-generation oral option in a crowded TYK2 landscape. The competitive setup matters for both companies: Sotyktu was the first-in-class TYK2 therapy in its class, and Takeda’s results move its program into direct clinical and market comparison. For payers and prescribers, head-to-head positioning can accelerate formulary and sequencing decisions. The update arrives as psoriasis developers push for durable efficacy, safety differentiation, and convenience—factors that increasingly decide outcomes beyond the initial phase of regulatory review.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.